CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
UNR844-Cl +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03809611
NCT03809611Phase 2Completed

A 3-month, Randomized, Placebo-controlled, Double-masked, Multi-center Study to Evaluate the Safety and Efficacy of Topical Ocular UNR844-Cl in Subjects With Presbyopia

Novartis Pharmaceuticals·interventional·Posted Jan 18, 2019·Updated May 11, 2022

In Brief

A Phase 2 clinical trial evaluating UNR844-Cl and Placebo for Presbyopia. Completed, enrolled 125 participants across 14 sites.

Detailed Summary

The purpose of this study was to assess the effect of topical UNR844-Cl (lipoic acid choline ester chloride) ophthalmic solution on near visual function in presbyopic subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 18, 2019
Enrollment StartApr 26, 2019
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.5 years ago

Interventions

UNR844-Cldrug

1.5% Ophthalmic solution for topical ocular administration

Placebodrug

placebo